Friday, 16 June 2017

Recent Report on Endometrial Cancer - Pipeline Review, H1 2017

Endometrial Cancer - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.
Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.
Complete report available @ Endometrial Cancer - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 37, 35, 1 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.
Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc Ability Pharmaceuticals SL Advenchen Laboratories LLC Aeterna Zentaris Inc ArQule Inc Arrien Pharmaceuticals LLC AstraZeneca Plc AVEO Pharmaceuticals Inc Bayer AG BeiGene (Beijing) Co Ltd BioNTech AG Biscayne Pharmaceuticals Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company CBT Pharmaceuticals Inc Cellceutix Corp Critical Outcome Technologies Inc CytomX Therapeutics Inc Eisai Co Ltd Eli Lilly and Company Endocyte Inc Esperance Pharmaceuticals Inc Exelixis Inc F. Hoffmann-La Roche Ltd Galena Biopharma Inc GamaMabs Pharma SA Genmab A/S GlaxoSmithKline Plc Glycotope GmbH Gradalis Inc Horizon Pharma Plc Immunocore Ltd ImmunoGen Inc Immunomedics Inc Incyte Corp Karyopharm Therapeutics Inc Lion Biotechnologies Inc MedImmune LLC Merck & Co Inc Merck KGaA Merrimack Pharmaceuticals Inc Merus NV Millennium Pharmaceuticals Inc Novartis AG Pfizer Inc Pharma Mar SA Pivot Pharmaceuticals Inc Puma Biotechnology Inc Sanofi Shenogen Pharma Group Ltd Sigma-Tau SpA Syndax Pharmaceuticals Inc Synthon Holdings BV Tesaro Inc
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home